| Using twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines R Marcec, R Likic Postgraduate medical journal 98 (1161), 544-550, 2022 | 147 | 2022 |
| Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: an open label, prospective cohort trial with matched controls M Calusic, R Marcec, L Luksa, I Jurkovic, N Kovac, S Mihaljevic, R Likic British journal of clinical pharmacology 88 (5), 2065-2073, 2022 | 88 | 2022 |
| Will vaccination refusal prolong the war on SARS-CoV-2? R Marcec, M Majta, R Likic Postgraduate medical journal 97 (1145), 143-149, 2021 | 58 | 2021 |
| Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID‐19 patients: A systematic review and meta‐analysis R Marcec, VM Dodig, I Radanovic, R Likic Reviews in medical virology 32 (6), e2397, 2022 | 24 | 2022 |
| Could fluvoxamine keep COVID 19 patients out of hospitals and intensive care units? R Marčec, R Likić Croatian medical journal 62 (1), 95-100, 2021 | 16 | 2021 |
| A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference R Marcec, VM Dodig, R Likic Journal of Infection 86 (2), 154-225, 2023 | 8 | 2023 |
| Evolving Trends and Economic Burden of Benzodiazepine Use: Insights From a 10-Year Predictive Model A Koren, L Koren, R Marcec, D Marcinko, R Likic Value in Health Regional Issues 40, 70-73, 2024 | 3 | 2024 |
| Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021 … E Primorac Padjen, R Marcec, M Zidar, I Padjen, T Katanec, B Anic, ... Rheumatology international 44 (2), 273-281, 2024 | 3 | 2024 |
| The relationship between vaccine acceptance and COVID-19 mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological data S Brnic, B Buric, R Marcec, R Likic Vaccine: X 15, 100391, 2023 | 3 | 2023 |
| Could fluvoxamine dose de-escalation increase treatment compliance without sacrificing efficacy in COVID-19 patients? R Marcec, R Likic Clinical pharmacokinetics 61 (9), 1321-1323, 2022 | 2 | 2022 |
| Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines—Much ado about nothing? R Marcec, R Likic British journal of clinical pharmacology 87 (9), 3632, 2021 | 2 | 2021 |
| Satisfaction and attitudes of Zagreb medical students towards online education during the COVID-19 pandemic R Marčec, M Majta, R Likić Liječnički vjesnik 142 (Supp 5), 0-0, 2020 | 2 | 2020 |
| Tackling medical deserts: unearthing factors that influence medical students’ attitudes and the path forward R Marcec, LA Seils, AI Gonzalez, K Dubas-Jakobczyk, A Domagała, ... Postgraduate Medical Journal 99 (1177), 1205-1206, 2023 | 1 | 2023 |
| Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say? R Marcec, VM Dodig, R Likic Journal of Infection 86 (1), 66-117, 2023 | 1 | 2023 |
| Seasonality of Hashimoto Thyroiditis: Infodemiology Study of Google Trends Data R Marcec, J Stjepanovic, R Likic JMIR Bioinformatics and Biotechnology 3 (1), e38976, 2022 | 1 | 2022 |
| Chronobiology: circadi-an rhythm, metabolism and metabolic disorders R Marčec Published online, 2016 | 1 | 2016 |
| Steven-Johnson Syndrome and Toxic Epidermal Necrolysis Following COVID-19 Vaccination: An Analysis of the EMA EudraVigilance Database VM Dodig, R Marčec, K Lakobrija, M Dobrošević, R Likić Liječnički vjesnik 144 (Supp 7), 42-42, 2022 | | 2022 |
| Could sertraline, an SSRI and sigma-1 receptor antagonist, increase the efficacy of anti-PD-1 checkpoint inhibitor therapy? R Marcec, R Likic Medical Hypotheses 167, 110931, 2022 | | 2022 |
| Vitamin C utilisation in 2020: have we bought a lemon? R Marcec, F Posavec, R Likic Postgraduate medical journal 98 (1163), 651-652, 2022 | | 2022 |
| Brave, new and divided post-COVID-19 world R Marcec, M Majta, R Likic Postgraduate medical journal 98 (e2), e133-e133, 2022 | | 2022 |
